Dynamic monitoring HER2 amplification of circulating DNA in metastatic colorectal cancer patients treated with cetuximab.

Zhiyu Chen(Chongqing University), Wenhua Li(University of Hong Kong), Rujiao Liu(Fudan University Shanghai Cancer Center), Xiaowei Zhang(Xuzhou Medical College), Mingzhu Huang(Shanghai Medical College of Fudan University), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Zhe Zhang(Huizhou Central People's Hospital), Xiaoying Zhao(Handan College), Weijian Guo(Fudan University Shanghai Cancer Center), Wen Zhang(Xidian University), Li‐Xin Qiu(Fudan University Shanghai Cancer Center)
Journal of Clinical Oncology
February 1, 2018
10.1200/jco.2018.36.4_suppl.714
Cited by 0

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
|Biochemical Pharmacology|2020|160
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis
|BMC Cancer|2014|146